Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer

[1]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[2]  Wiley Interscience,et al.  Locoregional treatment of peritoneal carcinomatosis from gastric cancer , 2008, Journal of surgical oncology.

[3]  A. Ohtsu.  Chemotherapy for metastatic gastric cancer: past, present, and future , 2008, Journal of Gastroenterology.

[4]  S. N. Kim,et al.  Treatment results for gastric cancer surgery: 12 years' experience at a single institute in Korea. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  A. García-Sastre,et al.  Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. , 2007, Cancer research.

[6]  L. Påhlman,et al.  Pharmacodynamic aspects of intraperitoneal cytotoxic therapy. , 2007, Cancer treatment and research.

[7]  S. Krishnamurthy,et al.  Differentially Regulated Interferon Response Determines the Outcome of Newcastle Disease Virus Infection in Normal and Tumor Cell Lines , 2006, Journal of Virology.

[8]  A. García-Sastre,et al.  Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[10]  S. Song,et al.  A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  A. García-Sastre,et al.  Newcastle Disease Virus V Protein Is a Determinant of Host Range Restriction , 2003, Journal of Virology.

[12]  L. Wein,et al.  Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. , 2002, Cancer research.

[13]  J. Nemunaitis.  Live viruses in cancer treatment. , 2002, Oncology.

[14]  T. Nakajima.  Gastric cancer treatment guidelines in Japan , 2002, Gastric Cancer.

[15]  K. Tanabe,et al.  Viral oncolysis. , 2002, The oncologist.

[16]  M. Peeples,et al.  Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. , 2001, Cancer letters.

[17]  K. Delman,et al.  Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer , 2000, Journal of Molecular Medicine.

[18]  P. Sugarbaker,et al.  Clinical Pathway for the Management of Resectable Gastric Cancer with Peritoneal Seeding: Best Palliation with a Ray of Hope for Cure , 2000, Oncology.

[19]  N. Nelson.  Scientific interest in Newcastle disease virus is reviving. , 1999, Journal of the National Cancer Institute.

[20]  P. Gregersen,et al.  A 15-Year Follow-up of AJCC Stage III Malignant Melanoma Patients Treated Postsurgically with Newcastle Disease Virus (NDV) Oncolysate and Determination of Alterations in the CD8 T Cell Repertoire , 1998, Molecular medicine.

[21]  M. Peeples,et al.  Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. , 1994, Cancer research.

[22]  T. Morrison,et al.  Mutations in the fusion peptide and heptad repeat regions of the Newcastle disease virus fusion protein block fusion , 1994, Journal of virology.

[23]  M. Peeples,et al.  Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. , 1994, Journal of the National Cancer Institute.

[24]  D. Murray,et al.  A ten-year follow-up on stage II Malignant Melanoma patients treated postsurgically with newcastle disease virus oncolysate , 1992, Medical oncology and tumor pharmacotherapy.

[25]  Michael B. Fernando,et al.  Newcastle disease virus selectively kills human tumor cells. , 1992, The Journal of surgical research.

[26]  J. Ajani,et al.  Current strategies in the management of locoregional and metastatic gastric carcinoma , 1991, Cancer.

[27]  K. Okajima,et al.  [Surgical treatment of far-advanced gastric cancer]. , 1986, Gan no rinsho. Japan journal of cancer clinics.

[28]  L. Csatary.  Viruses in the treatment of cancer. , 1971, Lancet.

[29]  C. Smith,et al.  Viruses in the treatment of cancer. , 1970, Lancet.